Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC grew its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 2.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 608,416 shares of the company’s stock after buying an additional 11,985 shares during the period. Kiniksa Pharmaceuticals International accounts for about 1.6% of Rice Hall James & Associates LLC’s holdings, making the stock its 13th largest holding. Rice Hall James & Associates LLC’s holdings in Kiniksa Pharmaceuticals International were worth $29,295,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in KNSA. Spruce Street Capital LP raised its position in shares of Kiniksa Pharmaceuticals International by 75.0% during the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after acquiring an additional 326,081 shares in the last quarter. Sei Investments Co. boosted its holdings in Kiniksa Pharmaceuticals International by 30.6% in the first quarter. Sei Investments Co. now owns 284,005 shares of the company’s stock valued at $13,675,000 after purchasing an additional 66,509 shares in the last quarter. First Trust Advisors LP increased its stake in Kiniksa Pharmaceuticals International by 3.1% in the first quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after purchasing an additional 293 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Kiniksa Pharmaceuticals International by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after purchasing an additional 128,417 shares during the last quarter. Finally, KBC Group NV acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter worth approximately $34,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 13,099 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $628,554.60. This represents a 51.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 628,427 shares of company stock worth $32,833,228 in the last 90 days. 51.98% of the stock is owned by insiders.

Kiniksa Pharmaceuticals International Trading Down 0.3%

Shares of NASDAQ KNSA opened at $62.84 on Friday. The stock has a market cap of $4.83 billion, a P/E ratio of 69.82 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a twelve month low of $26.27 and a twelve month high of $67.53. The stock has a 50 day moving average of $56.87 and a two-hundred day moving average of $49.97.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The business had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted $0.11 earnings per share. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.25 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KNSA. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $68.00.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.